Northwest Biotherapeutics Inc NWBO
We take great care to ensure that the data presented and summarized in this overview for NORTHWEST BIOTHERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NWBO
View all-
Moloney Securities Asset Management, LLC462KShares$129,4200.02% of portfolio
-
Opus Capital Group, LLC60.2KShares$16,8420.0% of portfolio
-
Williams Jones Wealth Management, Llc. New York, NY35KShares$9,8000.0% of portfolio
-
Ethos Financial Group, LLC King Of Prussia, PA23.7KShares$6,6360.0% of portfolio
-
Mai Capital Management20KShares$5,6000.0% of portfolio
-
Lee Danner & Bass Inc20KShares$5,6000.0% of portfolio
-
Alpha Mark Advisors, LLC Ft. Wright, KY14KShares$3,9210.0% of portfolio
-
Gofen & Glossberg LLC12.7KShares$3,5670.0% of portfolio
-
Advisors Management Group Inc10.3KShares$2,8750.0% of portfolio
-
Klcm Advisors, Inc.10KShares$2,8000.0% of portfolio
Latest Institutional Activity in NWBO
Top Purchases
Top Sells
About NWBO
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Insider Transactions at NWBO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 17
2023
|
Navid Malik Director |
BUY
Open market or private sale
|
Direct |
445,000
+66.85%
|
$0
$0.82 P/Share
|
|
Nov 16
2023
|
Navid Malik Director |
BUY
Open market or private sale
|
Direct |
125,000
+21.93%
|
$0
$0.84 P/Share
|
|
Apr 03
2023
|
Marnix L Bosch CHIEF TECHNICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
119,355
+50.0%
|
$0
$0.25 P/Share
|
|
Dec 01
2022
|
Jerry J Jasinowski Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,235
+50.0%
|
$592,935
$21.25 P/Share
|